Apollo Biowellness, Inc., Launches New Product Brand
Apollo Biowellness (OTC Pink: KOAN) has announced the launch of Cielo Skin Care, a new line of self-stable biologic cosmetics. The product line features exosome and placental-based formulations using human tissue as core ingredients, designed to enhance skin cell regeneration and combat aging effects.
The company plans to launch Cielo Skin Care in late Q3 2025 with market availability in Q4 2025. Distribution channels will include major retail, e-commerce, direct-to-consumer marketing, social media influencers, and TV shopping platforms. This launch complements Apollo's existing Doctor and Med Spa brand, Evolutionary Biologics.
Apollo Biowellness (OTC Pink: KOAN) ha annunciato il lancio di Cielo Skin Care, una nuova linea di cosmetici biologici autosufficienti. La gamma comprende formulazioni a base di esosomi e tessuto placentare umano come ingredienti principali, progettate per favorire la rigenerazione delle cellule cutanee e contrastare i segni dell'invecchiamento.
L'azienda prevede di lanciare Cielo Skin Care nella fine del terzo trimestre 2025 con disponibilit脿 sul mercato nel quarto trimestre 2025. I canali di distribuzione includeranno grandi retailer, e-commerce, vendite dirette al consumatore, influencer sui social media e piattaforme di shopping televisivo. Questo lancio integra il marchio medico e per spa di Apollo, Evolutionary Biologics.
Apollo Biowellness (OTC Pink: KOAN) ha anunciado el lanzamiento de Cielo Skin Care, una nueva l铆nea de cosm茅ticos biol贸gicos autocontenidos. La l铆nea incluye formulaciones basadas en exosomas y tejido placentario humano como ingredientes principales, dise帽adas para potenciar la regeneraci贸n celular de la piel y combatir los efectos del envejecimiento.
La compa帽铆a planea lanzar Cielo Skin Care a finales del tercer trimestre de 2025 con disponibilidad en el mercado en el cuarto trimestre de 2025. Los canales de distribuci贸n incluir谩n grandes minoristas, comercio electr贸nico, ventas directas al consumidor, influencers en redes sociales y plataformas de compras por TV. Este lanzamiento complementa la marca existente de Apollo para m茅dicos y spas, Evolutionary Biologics.
Apollo Biowellness (OTC Pink: KOAN)電� 靸堧鞖� 鞛愱皜 鞎堨爼順� 靸濍頃欖爜 頇旍灔頀� 霛检澑 Cielo Skin Care鞚� 於滌嫓毳� 氚滍憸頄堨姷雼堧嫟. 鞚� 鞝滍拡甑办潃 頂茧秬 靹疙彫 鞛儩鞚� 齑夓頃橁碃 雲疙檾 鞓來枼鞚� 鞕勴檾頃橂弰搿� 靹り硠霅� 鞚戈皠 臁办 旮半皹鞚� 鞐戩唽膦� 氚� 韮滊皹 靹彪秳鞚� 頃奠嫭鞙茧 頃� 鞝滍槙鞚� 韽暔頃╇媹雼�.
须岇偓电� 2025雲� 3攵勱赴 毵�鞐� Cielo Skin Care毳� 於滌嫓頃橁碃 2025雲� 4攵勱赴鞐� 鞁滍寪頃� 鞓堨爼鞛呺媹雼�. 鞙犿喌 瓴诫電� 欤检殧 靻岆Г鞐呾泊, 鞝勳瀽靸侁卑霝�, 歆侅爲 韺愲Г, 靻岇厹 氙鸽敂鞏� 鞚疙攲耄柛靹� 氚� TV 靽柬晳 頂岆灚韽检潉 韽暔頃╇媹雼�. 鞚措矆 於滌嫓電� Apollo鞚� 旮办〈 鞚橃偓 氚� 氅旊敂鞀ろ寣 敫岆灉霌滌澑 Evolutionary Biologics毳� 氤挫檮頃╇媹雼�.
Apollo Biowellness (OTC Pink: KOAN) a annonc茅 le lancement de Cielo Skin Care, une nouvelle gamme de cosm茅tiques biologiques auto-stables. La ligne comprend des formulations 脿 base d'exosomes et de tissu placentaire humain comme ingr茅dients principaux, con莽ues pour stimuler la r茅g茅n茅ration des cellules cutan茅es et combattre les effets du vieillissement.
La soci茅t茅 pr茅voit de lancer Cielo Skin Care 脿 la fin du 3e trimestre 2025 avec une disponibilit茅 sur le march茅 au 4e trimestre 2025. Les canaux de distribution comprendront les grandes enseignes, le commerce en ligne, la vente directe aux consommateurs, les influenceurs sur les r茅seaux sociaux et les plateformes de shopping t茅l茅vis茅. Ce lancement compl猫te la marque existante d'Apollo destin茅e aux m茅decins et aux med spas, Evolutionary Biologics.
Apollo Biowellness (OTC Pink: KOAN) hat die Einf眉hrung von Cielo Skin Care angek眉ndigt, einer neuen Linie selbststabiler biologischer Kosmetik. Die Produktreihe umfasst auf Exosomen und Plazenta basierende Formulierungen mit menschlichem Gewebe als Kernzutaten, die die Regeneration von Hautzellen f枚rdern und Alterungserscheinungen bek盲mpfen sollen.
Das Unternehmen plant die Markteinf眉hrung von Cielo Skin Care Ende Q3 2025 mit Verf眉gbarkeit im Markt in Q4 2025. Vertriebswege werden gro脽e Einzelh盲ndler, E鈥慍ommerce, Direktvertrieb an Endkunden, Social鈥慚edia鈥慖nfluencer und TV鈥慡hopping鈥慞lattformen umfassen. Dieser Launch erg盲nzt Apollos bestehende Arzt鈥� und Med鈥慡pa鈥慚arke Evolutionary Biologics.
- First-to-market with shelf-stable biologic skin care cosmetic
- Multiple distribution channels planned including retail, e-commerce, and TV shopping
- Complements existing Doctor and Med Spa brand for potential synergies
- No specific revenue projections or market size estimates provided
- Competitive landscape and pricing strategy not disclosed
radeditorformatted_6North Bergen, New Jersey--(Newsfile Corp. - August 21, 2025) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company"), is pleased to announce the launch of a new self-stable biologic cosmetic.
Figure 1
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10533/263268_a2b1b8e5841dc830_001full.jpg
Our new brand is called Cielo Skin Care, and it is a full line of consumer products using self-stabilized exosome and placental based products using human tissue as its core ingredient. Using such molecules will maximize the regeneration and regrowth of skin cells, thus improving the anti-aging effect that comes from ageing, sun exposure and other skin damage.
The Cielo Skin Care line will be launched in the late third quarter and will go to market in the fourth quarter. It will launch in major retail, e-commerce, direct-to-consumer marketing and via social media influencers and TV shopping outlets.
James W. Zimbler, President and CEO, stated, "We are proud to launch the FIRST shelf stable biologic skin care cosmetic. Coupled with our current Doctor and Med Spa brand, Evolutionary Biologics, we anticipate significant growth of our business model."
The Company uses the following handle on X at @ApolloBioKOAN to communicate with its shareholders
About Apollo Biowellness, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Corporate Contact
James W. Zimbler
President/CEO/Director
[email protected]
631-806-1420
X at @ApolloBioKOAN
To view the source version of this press release, please visit
FAQ
What is Apollo Biowellness's new Cielo Skin Care product line?
When will Apollo Biowellness (KOAN) launch Cielo Skin Care products?
How will Apollo Biowellness distribute its new Cielo Skin Care line?
What makes Apollo Biowellness's Cielo Skin Care unique in the market?
How does Cielo Skin Care fit into Apollo Biowellness's existing product portfolio?
